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Abstract
We study the problem of estimating the continuous response over time to interventions using
observational time series—a retrospective dataset where the policy by which the data are generated
is unknown to the learner. We are motivated by applications where response varies by individuals
and therefore, estimating responses at the individual-level is valuable for personalizing decision-
making. We refer to this as the problem of estimating individualized treatment response (ITR)
curves. In statistics, G-computation formula (Robins, 1986) has been commonly used for estimating
treatment responses from observational data containing sequential treatment assignments. However,
past studies have focused predominantly on obtaining point-in-time estimates at the population
level. We leverage the G-computation formula and develop a novel Bayesian nonparametric (BNP)
method that can flexibly model functional data and provide posterior inference over the treatment
response curves at both the individual and population level. On a challenging dataset containing
time series from patients admitted to a hospital, we estimate responses to treatments used in
managing kidney function and show that the resulting fits are more accurate than alternative
approaches. Accurate methods for obtaining ITRs from observational data can dramatically
accelerate the pace at which personalized treatment plans become possible.
Keywords: Bayesian nonparametric, Gaussian process, treatment response curves, time series
1. Introduction
Accurate models of actions and their effects on the state of the agent are critical for decision-making.
Learning of action-effect models is most straightforward from data where the learner can control
the choice of actions and observe their responses. However, such data are not always possible to
acquire. Alternatively, retrospective data may be available containing time series generated from
observing the actions from other agents. Estimating action-effect models from observational data,
where the learner cannot control the actions that are prescribed, or the actions may be prescribed by
a mechanism that is not known to the learner, is more challenging. We study an instance of this
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problem: specifically, we consider the problem of estimating the continuous response over time to
an action. We are particularly motivated by applications in medicine where accurate action-effect
models for estimating treatment effects can be used for personalizing therapy.
In statistics, the problem of estimating treatment effects from observational data containing
sequential treatment assignments has been studied extensively using approaches such as the G-
computation formula (Robins, 1986), G-estimation of structural nested models (Robins, 2004), inverse
probability of treatment weighted (IPTW) estimation of marginal structure models (van der Laan
and Petersen, 2007), doubly robust learning (Tsiatis, 2007; Zhao et al., 2015) with applications
to longitudinal data analysis (Hernán et al., 2000), survival analysis (Lunceford et al., 2002), and
adaptive treatment selections in clinical trials (Murphy et al., 2007a,b). A related problem in
reinforcement learning is off-policy evaluation where the goal is to estimate the value of a policy
(sequence of actions) from data collected by another policy (Sutton et al., 1998). For example,
doubly-robust estimators for policy evaluation have been developed for contextual bandits (Dudik
et al., 2011) and for sequential decision-making problems (Jiang and Li, 2015). See survey of example
techniques in Paduraru et al. (2012). In this paper, we use the G-computation formula to adjust
for time-varying confounding. We depart from the existing literature by using a novel Bayesian
nonparametric method to (1) flexibly model the longitudinal outcome over time, and (2) characterize
heterogeneity in treatment effects across individuals. 1
Bayesian nonparametric (BNP) methods (Ferguson, 1973; Müller and Mitra, 2013; Müller and
Rodriguez, 2013) are gaining popularity in longitudinal data analysis and treatment effect modeling
since they are characterized by parameters that live in an infinite-dimensional space, allowing one to
flexibly approximate arbitrary distributions. For flexible longitudinal data analysis, Silva (2016) uses
Gaussian process to model longitudinal outcome under different levels of interventions. In another
example, Chib and Hamilton (2002) use the Dirichlet Process prior to add flexibility in representing
the outcome and the treatment effects.
A number of related works have focused on heterogeneous treatment effects (HTE) by estimating
the effects conditional on covariates defining subpopulations. For example, Tian et al. (2014) and Imai
et al. (2013) apply regularized linear regression to select covariates characterizing subpopulations with
differential outcomes, Johansson et al. (2016) use neural network to learn a multi-layer representation
of high-dimensional covariates with differential outcomes. Other work use tree structure to partition
based on covariates that identify subpopulations with different outcomes (Foster et al., 2010; Su et al.,
2009) or different conditional treatment effects (Athey and Imbens, 2015). All of the above-mentioned
works focus on obtaining point-in-time estimates. Only recently, Huang et al. (2015) and Xu and Ji
(2014) have used parametric models to estimate treatment effects over time.
The proposed method advances state-of-the-art in a number of ways. First, in contrast with past
works that focus on modeling response at a point-in-time, this work obtains the continuous response
over time. Further, we obtain longitudinal responses from sparse and irregularly sampled observational
data. Second, the proposed BNP model flexibly models variations in treatment effects while borrowing
information across individuals. In applications such as education and healthcare where response across
individuals can vary widely, recovering individual level effects is more informative for decision-making.
Third, the fully Bayesian approach quantifies uncertainty at the individual level; this is particularly
important for individualization where the estimated effects maybe uncertain due to lack of data. A
key practical advantage of using nonparametric approaches is that they often provide better fits to
challenging data than using parametric model based methods. This is particularly important in our
application of estimating treatment response curves for physiologic time series.
1. This paper extends the method presented in (Xu et al., 2016).
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2. Longitudinal Treatment Response Model
As a running example, we use the application of estimating the longitudinal outcome for creatinine
level, an indicator of kidney function. Specifically, our goal is to obtain an individualized estimate
of the response over time for treatments given for modulating creatinine level. We consider the
problem of estimating the treatment responses from sparse, irregularly sampled data such as those
in electronic health records (EHRs). There are two key challenges that must be addressed. First,
in clinical data contained within EHRs, measurements are often not obtained at regular intervals,
and measurement schedules vary across individuals. For example, caregivers may choose to make
measurements once a day on some patients while multiple times a day on others. When the data
are collected at fixed regular intervals, discrete-time approaches that maintain estimates only at
specific points-in-time are adequate (e.g. Taubman et al. (2009)). To address this, we will employ
functional representations instead (Quintana et al., 2015). Another key challenge is the presence of
time-varying confounding (Robins, 1986, 1987). To correct for this confounding, our estimation is
based on Robin’s G-computation formula (Robins, 1986, 1987), a widely used approach in estimating
treatment effects from sequential data with time-varying confounding.
Time-varying confounding: To understand time-varying confounding, let us first consider the
simple example where a treatment tends to be assigned to sicker patients. Since these patients are
sicker and also more likely to die, without accounting for the assignment bias, one might erroneously
conclude this treatment is inferior. In the sequential-treatment assignment setting, such confounding
occurs because doctors use the measurement of a variable to determine whether or not to treat,
which in turn affects the variable’s value at a subsequent time. The casual graph is presented
on the left of Figure 1. In the graph, Y denotes the final outcome, L0, L1, and L2 denote the
intermediate measurements or covariates, and A1 and A2 denote the treatments. From observational
data, since we can only observe one treatment regime and one final outcome Y for each patient, we
apply Neyman-Rubin’s causal model (Sekhon, 2008) to define potential outcomes for the unobserved
counterfactuals. The model defines potential outcome Y (a1, a2) as the outcome when treatment
variables A1 and A2 are assigned to the values a1 and a2, respectively.
To adjust for time-varying confounding, G-computation formula makes two assumptions: consis-
tency and conditional ignobility. First, the potential outcomes are assumed to be consistent with
the observed outcomes, that is Y (a1, a2) = (Y |A1 = a1, A2 = a2). Second, the treatment received at
each time is randomly assigned (i.e. ignorable) conditional on past treatments and covariate history,
that is Y (a1, a2) ⊥ A1, A2|L0, L1, L2. As a result, we can obtain a new causal graph on the right of
Figure 1. Formally, we can write the conditional probability of potential outcome as
p(Y (a1, a2)|L0, L1, L2) = p(Y (a1, a2)|A1, A2, L0, L1, L2) (1)
= p(Y |A1 = a1, A2 = a2, L0, L1, L2),
where the first equality comes from the conditional ignobility and the second equality comes from
the consistency assumption. This is known as the likelihood component in the G-computation
formula. Below we introduce the notations used in the rest of the paper, and propose the longitudinal
treatment response model based on Eq. (1).
Notation: Assume we have observations Yi = {Yij : j = 1, .., Ji} from the ith individual at
(irregularly-sampled) times {ti1, ..., tiJi}. In addition, we have Xi = {Xij : j = 1, .., Ji}, where Xij
is a 1× p vector of observed covariates (e.g., age, gender, observation times) about this individual.
We also have treatments Ai = {Ail : l = 1, ..., Li} that were given to patient i at times {τi1, ..., τiLi},
where Ail = d for some treatment type d ∈ {1, .., D}. The value of a measurement Yi within an
interval (t, T ] is denoted by Yi,(t,T ]. The sets of measurements and treatments preceding a time t are
denoted by Yi,<t and Ai,<t, respectively.
Our goal is to obtain posterior inference for the treatment response curves at the individual and
population levels, and for the potential outcomes Yi,>t given any sequence of treatments conditioned
upon historical data. In contrast with prior methods that assume a parametric model for the potential
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Figure 1: Causal graph for adjusting time-varying confounding by the G-computation formula.
outcome (e.g., Hernán et al. (2000)), we propose below a Bayesian nonparametric model that models
longitudinal responses in three parts: a baseline progression with no treatments prescribed, responses
to treatments over time, and noises. We tackle the general setting of learning from data with multiple
exposures to the same treatment or different treatments under the assumption of additive treatment
effects.
We model the potential outcome Yij using a generalized mixed-effects model combining the
baseline progression and the treatment responses as follows:
Yij |Xij , Ai,<tij = b(Xij) + ui(tij)︸ ︷︷ ︸
baseline progression
+ fi(tij ;Ai,<tij )︸ ︷︷ ︸
treatment response
+ i(tij ;Ai,<tij)︸ ︷︷ ︸
noise
, j = 1, ..., Ji. (2)
2.1 Modeling Baseline Progression
b(Xij) is the fixed-effects component that captures the dependence of the outcome variable on
the observed covariates Xij . The features include time-invariant measurements (e.g., age, gender),
denoted by Xi0, and time-varying measurements (e.g., observation times, changes in physiology),
denoted by Xi1(tij). Here we model b(Xij) as a linear regression:
b(Xij ;βi) = X
T
ijβi = X
T
i0βi0 +Xi1(tij)
Tβi1. (3)
ui(tij) is the random-effects component that models the individual-specific deviations from b(Xij)
over time in baseline progression. We choose ui to be generated from a zero-mean Gaussian process
with a structured covariance Kui(σ2ui, ρui) = Cov(ui(tij),ui(tij′)) = σ2uiρ
|tij−tij′ |
ui . Here, ρui ∈ (0, 1).
This represents an exponential covariance function, where σ2ui is referred as a scale parameter and
ρui as a smooth parameter. Similar choices were made by Quintana et al. (2015) in their application
of modeling functional data. A different choice for both the mean and the covariance kernel can be
made depending on the properties of the data; see Schulam and Saria (2015) for a different example
of the baseline model for modeling progression in chronic diseases.
2.2 Modeling Treatment-Response
We focus on scenarios where treatment choices are discrete and treatment effects are additive. Given
the set of treatments Ai,<tij preceding time tij , we formulate the treatment response model as:
fi(tij ;Ai,<tij ) =
∑
l:τil<tij
gi,Ail(tij − τil), (4)
where gi,Ail(tij − τil) denotes the response curve of individual i for treatment Ail that was given at
time τil. To estimate the cumulative effect at tij , the response curves from the treatment set Ai,<tij
are added. We parameterize the function gid(t) as
gid(t) =
{
b0 + α1id/[1 + exp(−α2id(t− γid/2))], if 0 ≤ t < γid
bid + α0/[1 + exp(α3id(t− 3γid/2))], if t ≥ γid,
(5)
4
Figure 2: Examples of treatment response curves
with five free parameters {α1, α2, α3, γ, b}; here, the collection of individual-specific treatment response
parameters α1id ’s are short-handed to α1 and so on.
The motivation for choosing this particular form of the gid(t) function is to obtain a flexible
asymmetric “U” shape curve, as shown in Figure 2. We concatenate two sigmoid curves and allow
the parameters for the two sigmoid functions and the point of switching between the two sigmoids to
vary so that it can flexibly capture responses where a marker may either increase or decrease and
eventually converges to a stable value. In Figure 2, we present several examples of such curves, and
highlight one particularly for g(t;α1 = 5, α2 = 0.2, α3 = 0.4, γ = 40, b = 2). Here, α1 ∈ < represents
the curve’s maximum value and the sign of α1 determines whether the treatment increases (i.e.
α1 > 0) or decreases (i.e. α1 < 0) the target marker value. α2 ∈ (0, 1) and α3 ∈ (0, 1) individually
model the “steepness” of the two sigmoid curves; γ ∈ < denotes the switching point; b denotes the
value that the curve stabilizes and is constrained such that b/g(γ) ∈ (0, 1). Lastly, to make the
gid(t) function well defined, we set b0 = −α1id/[1 + exp(α2idγid/2)] for attaining gid(0) = 0, and
α0 = (a1id + 2b0 − bid)/(1 + exp(−a3idγid/2)) for attaining a unique peek value at t = γid.
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Figure 3: An illustration of additive treatment responses over time in single regime. (a) In black,
an example baseline progression for the target outcome under no treatment. In red, we
show the time of treatment assignment and the treatment-response curve. (b) In blue,
the outcome over time is shown—obtained by adding the baseline progression and the
treatment response curve. (c) The outcome over time when the treatment is assigned
multiple times—the timing of the assignments are shown with vertical red lines.
In Figure 3, we illustrate the cumulative effects by adding multiple treatment responses. In Figure
3 (a), the black line denotes the increasing outcome due to an increasing baseline progression under
no treatment. For example, in individuals with chronic kidney disease, their kidney function markers
under no treatment become worse over time. In Figures 3 (a-c), the vertical red lines denote times
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when the treatment was prescribed. The reduced outcome values in the case of a single treatment
versus multiple sequential treatments are shown in blue in Figures 3 (b) and 3 (c) respectively.
Figures 3 (b-c) illustrate the cumulative effect from multiple treatment assignments.
2.3 Modeling Noise
We model the noise in two parts: the independent random noise 0ij for individual i at each time
point tij and the time-dependent random noise ′d(t) for treatment type d within its effective window
Wd. We model this additional noise because adding the effects of treatments can introduce higher
uncertainty and error into the outcome model. The noise is time-dependent because the uncertainty
reduces as the time from treatment administration increases and the effects diminish. So we formulate
the overall noise as
i(tij ;Hij) = 0ij +
∑
l:τil<tij
′Ail(tij − τil), (6)
where 0ij ’s are i.i.d. Gaussian distributed with mean zero and variance σ2i , 
′
d(t)’s are jointly Gaussian
distributed with mean zero and structured covariance Kd(σ2′d , ρ′d) = Cov(
′
d(t), 
′
d(t
′)) = σ2′dρ
|t−t′|
′d
.
2.4 A Hierarchical Prior for Estimating Individualized Treatment Response (ITR)
Curves
We posit a nonparametric hierarchical prior on the parameters in the baseline progression and the
treatment response model. At the population level, this allows our model to flexibly capture hetero-
geneity in treatment response across individuals without specifying the number of subpopulations.
Further, our model can borrow information across individuals to estimate one individual’s treatment
response by a hierarchical prior. It is worth noting that overfitting or lack of reliable estimates is a
key concern when fitting treatment responses at the individual level. Within the proposed approach,
we obtain the full posterior distribution over the individual’s treatment response rather than a point
estimate for the parameters. Further, when little data are available on an individual, their ITR
estimate is similar to that of the population. However, as more data are collected, the posterior
distribution over the ITR becomes more informative regarding if and how the individual’s ITR differs
from other individuals.
Bayesian nonparametric approaches such as Dirichlet process (DP) and DP mixture have been
widely used in clustering time-series data. For example, Ren et al. (2015) have applied DP priors
in latent factor models to cluster multiple housing price data streams. Nieto-Barajas et al. (2014)
uses a generalization of DP mixture—Possion-DP priors—in linear dynamic models to group stock
exchange data. We use the DP mixture to cluster the parameters for the fixed-effects component of
the baseline progression and the treatment response curves, and use the DP mixture of Gaussian
processes to cluster the random-effects component for the baseline progression. The DP mixture
of GPs has been used to identify and group the sub-divisions in each individual’s gene expression
(Hensman et al., 2015) or disease trajectories (Ross and Dy, 2013). We use DP mixture of GPs to
group individuals’ baseline deviations on their similarity in the GP’s kernel parameters.
2.4.1 Background on the Dirichlet Process Mixture
We briefly describe the DP and the DP mixture (DPM). Ferguson (1973) introduced the DP prior
as a probability distribution on an infinite dimensional measurable space of probability measures.
The stick-breaking construction by Sethuraman (1994) provides an intuitive and interpretable
representation of the DP. Let G0 be a known distribution and let M > 0 be a positive constant.
6
Then we say G ∼ DP (G0,M) provided
G(·) =
∞∑
k=1
ωkδθk(·), θk iid∼ G0,
where δθk(·) defines point mass at θk and ωk’s are defined as
ωk = Vk
k−1∏
r=1
(1− Vr), Vk ∼ Beta(1,M).
Thus G is a random distribution that is discrete with probability one. G0 is the base or centering
distribution since E(G) = G0. The discrete nature of the DP makes it inappropriate for modeling
continuous data where units within a partition share similar rather than the same parameter.
Therefore, DPM extends DP by introducing a continuous kernel centered at θk instead of a point
mass δθk . Let y1, y2, . . . be i.i.d. samples and f(·|θ) be a parametric density function, we can write
the stick-breaking construction of the DPM as
yi | (ωk), (θk) ∼
∞∑
k=1
ωkf(·|θk), θk ∼ G0.
2.4.2 Hierarchical Individualized Treatment-Response (ITR) model
We leverage the DPM prior to cluster both the baseline progression and the treatment response
parameters—while allowing individual-specific variability—and obtain a hierarchical treatment-
response model as shown in Figure 4. Specifically, let bi denote the sum of the fixed-effects
component b(XMi ) and the random-effects component ui in the baseline progression. Then based on
the description in Section 2.1, bi follows the distribution
p(bi|ϕi) = N ((XMi )Tβi,Kui), (7)
Kui(tij , tij′ ;σ2ui, ρui) = σ2uiρ
|tij−tij′ |
ui ,
where ϕi = {βi, σ2ui, ρui} denotes all the individual-specific baseline progression parameters. We
posit a DPM prior on ϕi’s, and obtain the following distributions
p(ϕi) =
∞∑
k=1
ωkN (βi;β∗bk ,Σ∗bk)
N (log(σ2ui);µ∗σ′uk , σ
2
σ′u0
)
σ2ui
N (logit(ρui);µ∗ρ′uk , σ
2
ρ′u0
)
(1− ρui)2 ,
(8)
ωk = Vϕk
k−1∏
r=1
(1− Vϕr ),
p(Vϕk) = Beta(1,M1),
p(β∗bk ,Σ
∗
bk
, µ∗σ′uk , µ
∗
ρ′uk
) = NIW(β∗bk ,Σ
∗
bk
;β0, κ0, θ0,S0)N (µ∗σ′uk ;µσ′0 , σ
2
σ′0
)N (µ∗ρ′uk ;µρ′0 , σ
2
ρ′0
).
For parameters that lie in real space we assume they are sampled from a Gaussian distribution. For
parameters that are constrained, such as σ2ui ∈ (0,+∞) and ρui ∈ (0, 1), we transform the support
of these variables into real space first and posit Gaussian priors on the transformed unconstrained
variables. This requires a calculation of the additional Jacobian adjustment |det J(T−1(y))| for each
transformation y = T (x) (Olive, 2014). A detailed description of deriving the Jacobian adjustment is
given in Appendix A.
We let θ∗ϕk = {β∗bk ,Σ∗bk , µ∗σ′uk , µ
∗
rho′uk
} denote the component-specific parameters that the trans-
formed ϕi’s are centered at. We introduce a discrete latent variable Zϕi to indicate the mixture
7
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Figure 4: Graphical representation of the hierarchical treatment response model. Hidden variables
are circled; observed outcome variables are shaded; observed input variables are filled.
component associated with individual i, and sample the Zϕi ’s from a Multinomial distribution over
the weight ωk’s. The hyperparameter M1 controls the degree of clustering and generates the Vϕk ’s to
formulate the associated component weight ωk’s. Lastly, we let a1 = {β0, κ0, θ0,S0, µρ′0 , σ2ρ′0 , µσ′0 , σ
2
σ′0
}
denote all the hyperparameters that are used in θ∗ϕk ’s base distribution. In our applications, as
discussed later in Section 4.2 and 4.3, these hyperparameters are chosen to construct broad (and
uninformative) base distributions.
For the treatment response model, fi is defined as Eq. (4). We let φid = {α1id , α2id , α3id , γid, bid}
denote the individual-specific treatment parameters in the gid(t) function in Eq. (5). Similarly, we
put DPM priors on φid’s, and obtain the following distributions
p(φid) =
∞∑
k=1
ωdkN (T−1(φid);µ∗φ′dk ,Dφ′0)|ζid|/(1− α2id)
4, (9)
ωdk = Vφdk
k−1∏
r=1
(1− Vφdk),
p(Vφdk) = Beta(1,M2d),
p(µφ′id) = N (µφ′id ;µd0 ,Dd0),
where T−1(φid) = {α1id , logit(α2id), logit(α3id), γid, logit(bid/g(γid))} is a real-space vector trans-
formed from φid’s, and ζid = −1/g(γid)(1− b/g(γid))2 is the Jacobian adjustment computed from
the transformation. A detailed description is given in Appendix A.
We let θ∗φid = {µ∗φ′dk} denote the component-specific parameters that T
−1(φid)’s are centered
at. We introduce a discrete latent variable Zφid to indicate the mixture component associated
with individual i’s response to dose type d, and sample Zφid ’s from a Multinomial distribution
over the weight ωdk’s. The hyperparameter M2d controls the degree of clustering and generates the
Vφk ’s to formulate the associated component weight ωdk’s. We let a2d = {µd0 ,Dd0} denote all the
8
hyperparameters that are used in θ∗φid ’s base distribution. In our applications, as discussed later in
Section 4.2 and 4.3, these hyperparameters are chosen to construct broad (and uninformative) base
distributions.
For the noise model, based on the description in Section 2.3, i follows the distribution
p(i|σ2i ,σ2′ ,ρ′) = N (0, σ2iIJi +K′i), (10)
K′i(tij , tij′ ;σ2′ ,ρ′) =

∑
l σ
2
′Ail
ρ
|tij−tij′ |
′Ail
, ∀l s.t. tij > τil, tij′ > τil,
0 , otherwise.
To complete the prior specification ,we put inverse gamma (IG) on the scale parameter σ2i , and
transform the constrained parameters σ2′d and ρ′d into real space then posit Gaussian priors on the
transformed unconstrained variables:
p(σ2i) = IG(s, ν), (11)
p(σ2′d
) = N (log(σ2′d);µ1 , σ
2
1)/σ
2
′d
,
p(ρ′d) = N (logit(ρ′d);µ2 , σ22)/(1− ρ′d)2.
3. Inference
We use MCMC to approximate the posterior distributions of the parameters in the proposed model.
Consider the joint posterior
p(u,f ,ϕ,φ, σ2 ,σ
2
′ ,ρ′ | Y ) (12)
∝
{ I∏
i=1
p(Yi, bi,fi | ϕi,φi, σ2i ,σ2′ ,ρ′)
}
p(ϕ)p(φ)p(σ2i)p(σ
2
′)p(ρ′)
=
{ I∏
i=1
p(Yi | bi,fi, σ2i ,σ2′ ,ρ′)p(bi | ϕi)p(fi | φi)
}
p(ϕ)p(φ)p(σ2 )p(σ
2
′)p(ρ′),
the first term in the product is N (Xibi + fi, σ2iIJi +K′i) with K′i specified in Eq. (10), the second
term is defined in Eq. (7), the third term is deterministic and specified in Eq. (4). We factorize the
remaining terms as { I∏
i=1
{
p(ϕi)
D∏
d=1
p(φid)
}}{ I∏
i=1
p(σ2i)
}{ D∏
d=1
p(σ2′d
)p(ρ′d)
}
,
with each distribution specified in Eq. (8, 9, and 11) respectively.
For the infinite-dimensional DPM priors on ϕi and φid, we approximate these using a truncated
stick-breaking process that was developed by Ishwaran and James (2001). Ishwaran and James
(2001) justify that the truncated process greatly reduces computations and can closely approximate
a full Dirichlet process when the truncation level is large relatively to the number of observations.
Based on Theorem 2 in Ishwaran and James (2001), for experiments where we have fewer than 500
time series, a truncation level of 20 for the number of clusters provides an approximation with error
bound of 1.12e− 05 on the L1 distance between the true marginal distribution and the approximate
marginal distribution of the data. Given the truncation approximation, it allows us to use standard
MCMC algorithms to update the parameters in the finite-dimension space. Particularly, we develop a
Gibbs sampler. We posit conjugate priors on the parameters; this allows us to obtain the conditional
distributions for the variables within each Gibbs loop in closed form. Specifically, the forms of these
conditional distributions for the component indicator variables Zϕi and Zφid are Multinomial, for
9
the component-level variables β∗bk , Σ
∗
bk
are Normal-inverse-Wishart, for µ∗σ′uk
, µ∗ρ′uk
and µ∗φdk are
Gaussian, for Vϕk and Vφdk are Beta, and for the concentration parameters M1 and M2d are Gamma.
In addition to the DPM related parameters, we also use Gibbs sampler to infer βi, bi and σ2i . The
forms of these conditional distributions are all Gaussian. Detailed descriptions of deriving the Gibbs
samplers are in Appendix B.1 and B.2.
For the remaining variables, the conditional distributions cannot be derived in closed form. Thus
we use a Metropolis-Hastings sampler. Particularly, for the unconstrained variables α1id and γid, we
choose the proposal distribution to be normal with standard deviation of 0.3. For the constrained
variables σ2ui ∈ (0,+∞) and σ2′d ∈ (0,+∞), we choose the truncated normal distribution (Greene,
2003) with standard deviation of 0.3. For variables ρui, α2id , α3id and bid/g(γid) that are constrained
in (0, 1), we choose normal with standard deviation 0.15 to propose a new sample. Then, we reflect
the new sample by 0 or 1, probably multiple times if needed, to map it back onto the support (0, 1).
A detailed description of the Metropolis-Hasting sampler is in Appendix B.3. In our experiments,
which will be discussed in Section 4.2, these proposal distributions performed well (with acceptance
rates ranging from 0.14 - 0.22 across the chains).
4. Numerical Results
We evaluate the proposed model in three experiments, including a simulation study and two obser-
vational studies. We first conduct a simulation study to evaluate whether the proposed model can
uncover the true treatment response curves and the extent to which the quality of the recovered
curves depends on the choice of the hyperparameters. Then, we evaluate the model’s performance
on estimating treatment responses using two observational data sets. With the first dataset, we
estimate the individual’s response curves to treatments for managing creatinine levels. High creatinine
levels can indicate kidney function deterioration, and renal replacement therapy (RRT) can be given
for treatment. With the second dataset, we estimate the effects of diuretics on fluid balance. In
conditions of critical illness, the body’s ability to remove excess water can deteriorate. Diuretics can
be administered to remove the excess sodium and water from the body.
4.1 Simulation Study
Datasets. We simulate 200 trajectories with each trajectory’s duration uniformly sampled from 18-24
hours. To sample observation times within a trajectory, we sample the time for the next observation
uniformly from 5-15 minutes at each a given time. The resulting trajectories have on average 126
measurements. To sample treatment times, we sample the time for the next treatment uniformly
from 60-80 minutes at each given time. At each time, we also sample the treatment assignment
conditioned on previous assignments and outcomes. This satisfies the ignobility assumption described
in Section 2. We generate three types of treatments including the following: no treatment, treatment
1 that has an increasing effect on the outcome, and treatment 2 that has a decreasing effect. We
designate the conditional probabilities to maintain the outcome within a “normal” range with high
probabilities. For example, given treatment 1 was prescribed at the previous time point, we assign
high probability to generate treatment 1 again at the current time point if the outcome is still low,
but assign low probability to generate treatment 1 if the outcome has been increased into the normal
range. The detailed conditional probabilities are specified in Table 1, where At denotes the treatment
assignment at time t (0 for no treatment, 1 for treatment 1, and 2 for treatment 2), and Yt indicates
the outcome level at time t (0 for below, 1 for within, and 2 for above the normal range). We define
normal range as [15, 25] in our simulation. Figure 5 shows one example trajectory: the black points
are the observations of the outcome, the colored vertical dotted lines denote when the treatments
are prescribed, and different colors refer to different treatment types. In average, we generate 9
treatments per trajectory.
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At At−1 Yt−1 P (At|At−1, Yt−1) At At−1 Yt−1 P (At|At−1, Yt−1) At At−1 Yt−1 P (At|At−1, Yt−1)
0 0 0 0.3 0 1 0 0.3 0 2 0 0.6
1 0 0 0.5 1 1 0 0.6 1 2 0 0.3
2 0 0 0.2 2 1 0 0.1 2 2 0 0.1
0 0 1 0.8 0 1 1 0.8 0 2 1 0.8
1 0 1 0.1 1 1 1 0.1 1 2 1 0.1
2 0 1 0.1 2 1 1 0.1 2 2 1 0.1
0 0 2 0.3 0 1 2 0.6 0 2 2 0.1
1 0 2 0.2 1 1 2 0.1 1 2 2 0.1
2 0 2 0.5 2 1 2 0.3 2 2 2 0.8
Table 1: Conditional probability table for simulating treatment assignments
Figure 5: A simulated trajectory: the red dotted lines denote the simulated baseline progression, the
vertical dotted lines denote the simulated treatments (green is treatment 1 and blue is
treatment 2), and the black dots denote the resulting observations.
To sample observation values, we individually sample the baseline progression, the treatment
responses, and the noise terms that are specified in Eq. 2. In the baseline progression, we choose
feature Xij =
{
1, tij , t
2
ij
}
for individual i at observation time tij . We assume the parameters βi,
σ2ui, and ρui are sampled from a three-mixture model. Specifically, the three-mixture component
parameters for βi’s are
{
5, 5, 3
}
,
{
30,−5,−3} and {10,−2,−1}, the component parameters for σ2ui’s
are 0.12, 0.12, and 0.12, and the component parameters for ρui’s are 0.1, 0.9, and 0.5. We assign
each individual to one of the three components with equal probabilities. Given the assignment to
a component, we sample the individual’s parameters from a Gaussian distribution centered at the
component parameters with a small variance of 0.12 (σ2ui and ρui were transformed into real-space).
In the left panel of Figure 6 (a), we show the resulting baseline progressions from the three-mixture
components.
For each treatment, the treatment response parameters
{
α1id , α2id , α3id , γid, bid
}
are sampled from
a three-mixture model. The component parameters for treatment 1 are specified as
{
10, 0.9, 0.4, 10, 0
}
,{
5, 0.9, 0.9, 5, 0
}
, and
{
8, 0.7, 0.7, 15, 0.001
}
; the component parameters for treatment 2 are specified
as
{−10, 0.9, 0.7, 20, 0}, {−6, 0.5, 0.5, 15, 0}, and {−8, 0.4, 0.3, 25, 0}. For each treatment, we assign
each individual to one of the three components with equal probabilities. Given the assignment to a
component, we sample the individual’s treatment response parameters from a Gaussian distribution
centered at the component parameters with a small variance of 0.32 (α2id , α3id , and bid/g(γid) were
transformed into real-space). In the right two panels of Figure 6 (a), we show the resulting treatment
response curves sampled from each of the three-mixture models.
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For noise, we sample the i.i.d. noise from zero-mean Gaussian distribution with variance of 0.32.
For each given treatment, we sample the time-dependent noise from the zero-mean multivariate
Gaussian distribution with the exponential kernel specified by σ2′d = 0.1
2 and ρ′d = 0.9.
Experimental setup. For the fixed-effect component in the baseline progression, we posit a
non-informative Normal-inverse-Wishart base distribution NIW(0, 1, p+2, Ip+2) on the regression
coefficients, where p = 3 since we use 3 covariates in simulation. For the random-effect component
in the baseline progression, we posit a non-informative Gaussian base distribution N (logit(0.5), 4)
(covers range (0.02, 0.98) with 95% confidence) on the transformed smooth parameters ρui’s defined in
the exponential Gaussian process kernel. GP estimation is known to be consistent in estimating latent
functions with a known convergence rate (van der Vaart and van Zanten, 2009), but is asymptotically
unidentifiable in estimating the parameters in the Mate´rn class covariance functions (including
exponential covariance) with infill domain (Zhang, 2004). Thus, we conduct a sensitivity analysis to
study the quality of the recovered curves based on different choices of these scale parameters. For
real applications, as discussed in Section 4.2 and 4.3, we will posit strong priors on these parameters
to make them concentrated at small values.
For the treatment response model, we posit a multivariate Gaussian base distribution on the trans-
formed response parameters for each treatment type: N ({8, logit(0.5), logit(0.5), 10, logit(0.5)}, 4I5)
for treatment 1 and N ({−8, logit(0.5), logit(0.5), 20, logit(0.5)}, 4I5) for treatment 2. We choose
these base distributions to be non-informative except for the peak effects and the change points that
are chosen based on prior knowledge. For real applications, as discussed in Section 4.2 and 4.3, we
also choose these priors based on expert domain knowledge.
For the i.i.d noises, we posit a non-informative Inverse-Gamma prior IG(1,1) on their variances.
For the time-dependent noises in treatment responses, we posit a non-informative prior N (logit(0.5), 4)
on the transformed smooth parameters, and posit a strong prior N (log(0.12), 0.32) on the transformed
scale parameters to avoid identifiable problems.
We randomly initialize one chain and run it for 5, 000 iterations with a burn-in of 2, 500 iterations.
For each individual, we estimate the baseline progression and the treatment response curves based on
the parameters sampled at each iteration after the burn-in. Afterwards, we average over the 2, 500
estimates to obtain the mean baseline progression and the mean treatment response curves for each
individual. To evaluate the model performance, we recover each individual’s component assignments
from the last iteration and compare the resulting distribution with the simulation truth.
Results. In Figure 6 (b-f) we present the recovered baseline progressions and treatment response
curves based on different scale parameters. Both the individual estimates and the three-mixture
component estimates in the baseline progression and the treatment response curves are accurately
recovered when the scale parameter is set to be that of the truth (i.e. 0.12). The individual baseline
progression and treatment response curves are mostly recovered and the three-mixture component
are still accurately recovered when the scale parameters are set to be close to the truth (i.e. 0.052 or
0.52). When the scale parameters are set to be large or unclamped, the model become too flexible
so that the variations in the treatment responses could partially be explained by the variations of
the baseline progressions themselves. Therefore, both the peak values and the change points in the
treatment response curves cannot be estimated accurately.
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Figure 6: The true baseline progressions and treatment response curves used in simulation and the
results recovered by the proposed model (different colors denote the different mixture
components)
4.2 Observational Study: Estimating Heterogeneous Response Curves to Renal
Replacement Therapy
We evaluate the proposed model on the task of estimating patients’ responses to renal replacement
therapy (RRT), a type of treatment to manage kidney function. Acute kidney injury (AKI) is a
common complication in the intensive care unit (ICU). Furthermore, studies show that the mortality
in AKI patients who depend on RRT can be as high as 80% (Tolwani, 2012; Bellomo et al., 1999).
The decision to initiate RRT is complicated and not all the patients respond to RRT in the same
manner. Thus, an individualized assessment tool is needed to determine which patients will benefit
from RRT and which will not (Mehta, 2016).
Datasets. We fit our models on electronic health record data from patients admitted to the
Beth Israel Deaconess Medical Center in Boston. The data are publicly available in the MIMIC
(Multiparameter Intelligent Monitoring in Intensive Care)-II Clinical Database (Saeed et al., 2002).
We estimate the effects of three types of RRT: Intermittent Hemodialysis (IHD), Continuous Veno-
Venous Hemofiltration (CVVH), and Continuous Veno-Venous Hemodialysis (CVVHD). We use
creatinine level as the patient’s outcome. The creatinine level can increase when the kidney function
declines. Figure 7 presents a typical trajectory from MIMIC-II patients who are prescribed RRTs.
To decrease the creatinine levels, RRT can be initiated as an artificial replacement of the kidneys’
function. After creatinine levels are decreased into the target range, RRT is discontinued and can be
re-initiated when needed. Because RRT does not cure kidney disease permanently, creatinine levels
rise again after a period of discontinuation on RRT. This is handled using a time-varying covariate
as discussed in the experimental setup.
To select individuals from the database, we include the patients who were prescribed IHD, CVVH,
and CVVHD during their ICU stay. We exclude the patients who have less than 15 observations of
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Figure 7: An example trajectory of managing creatinine levels within multiple treatment regimes.
Black dots denote the observed creatinine levels. Vertical dashed lines denote the timing
of treatments.
creatinine levels following the first elevated creatinine blood test measurement (i.e. creatinine level
higher than 1.3 mg/dL for men and 1.1 mg/dL for women). The dataset contains 428 trajectories
with a total of 16, 593 creatinine observations. Each individual trajectory has an average duration
of 23 days. IHD are usually prescribed 3 times a week, each treatment lasting 3 to 6 hours or less
(Pannu and Gibney, 2005). CVVH and CVVHD are two modalities of Continuous Renal Replacement
Therapy (CRRT), and they are intended to be applied for 24 hours per day in ICU (Pannu and
Gibney, 2005). The dataset contains a total of 525 instances of IHD, 186 of CVVH, and 981 of
CVVHD. Creatinine levels were standardized by the population mean of 3.16 and standard deviation
of 1.87.
Baselines. We compare the performance of ITR with three baselines: the pop model, individual
model, and sub-pop model. First, we evaluate against what we refer to as the pop model, which
estimates treatment responses at the population level and does not take into account variations across
individuals. The pop model is an instance of ITR where the baseline progression and the treatment
response (transformed) parameters are drawn uniformly from a broad prior. To evaluate the extent
to which individualizing the treatment response estimates is important, we also compare ITR against
a second baseline called the indivdiual model. In the individual model, the parameters are drawn
independently from a broad prior so that each individual samples its own set of parameters. Lastly,
we compare ITR against a third baseline, called the sub-pop model, where the parameters are drawn
from a DP instead of a DPM. This allows treatment responses to vary by subgroups but there is no
explicit representation for differences across individuals within a subgroup.
Experimental setup. We assume that the fixed-effects component in the baseline progression
is a linear regression model. We include the patient’s age and weight as two baseline covariates. In
addition, we include a time-varying covariate as follows. As described above, creatinine increases over
time once RRT has been discontinued. This drift is modeled using a function of time—in this case,
log(t−W ), where t is the time since last RRT discontinuation. W is the window of time it takes
for creatinine to stabilize after RRT discontinuation. W was selected based on clinical guidance:
W = 6 hours for IHD and W = 12 hours for CRRT. In Figure 7, we show an example creatinine
trajectory and the example window W. Thus in total, we have p = 4 covariates (i.e., age, weight,
time, and 1 for the intercept). We posit a non-informative Normal-inverse-Wishart base distribution
NIW(0, 1, p+ 2, Ip) for the regression coefficients. We posit a strong prior N (log(0.12), 0.32) on the
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Figure 8: Comparison of ITR vs. baseline models prediction errors on creatinine.
transformed scale parameters in the exponential Gaussian process kernel and a non-informative prior
N (logit(0.5), 4) on the transformed smooth parameters.
For the treatment response model, we posit a Gaussian prior on the peak effects with the means
chosen by the domain expert. Specifically, these were set as N (−2, 1) for IHD and N (−1, 1) for
both CVVH and CVVHD. Similarly, we posit a Gaussian prior on the change points with the means
chosen by the domain expert based on the expected duration over which the treatment takes effect.
Specifically, these were set as N (1 hr,100 hrs) for IHD and N (12 hrs, 100 hrs) for both CVVH and
CVVHD. We posit non-informative Gaussian priors N (logit(0.5), 4) for the two steepness parameters
and the ratio of the long-term effect to the peak effect.
For the noise, we posit an Inverse-Gamma prior IG(1, 1) on the variances of the i.i.d. noises. We
posit strong priors N (log(0.12), 0.32) on the scale parameters for the time-dependent noises, and
non-informative priors N (logit(0.5), 4) for the smooth parameters.
Evaluation. We use the prediction error on a held-out test set to compare the proposed model
to the baseline models. The proposed approach can update parameters online but for the sake of this
comparison, we treat the first 50 observations from each individual as training data and the remainder
as test. Predictions of the measurements are made under the treatment strategy prescribed in the
test set. Since the creatinine levels are measured on average twice a day and treatment decisions are
made at the granularity of days, we report the prediction errors for seven days following the end
of training. We run 4 randomly initialized chains each for 5,000 iterations with a burn-in of 2,500
iteration and thin of 50 iterations.
To calculate the prediction error, we predict each patient’s creatinine levels for seven days based
on the individual parameters sampled at every 50 iterations after the burn-in. We compute prediction
means individually by averaging each patient’s 200 predictions (from the 4 chains each with 50
predictions), and obtain 95% credible intervals individually using the quantiles of the 200 predictions.
We calculate the root mean squared error (RMSE) on each individual’s prediction mean, and average
across the individuals to obtain the overall prediction error and the 95% credible interval.
Quantitative Results. In Figure 8, we report the mean prediction errors with the 95% credible
intervals for ITR and the three baseline models. ITR outperforms the baseline models significantly
after day 3. Individual model outperforms sub-pop model, and after day 4, it significantly outperforms
pop model. Sub-pop model outperforms pop model significantly after day 6. ITR outperforms sub-pop
model because ITR is more expressive since it allows individual-level heterogeneity and information to
be shared across individuals in the same group. On the other hand, ITR also outperforms inidividual
model because the lack of subgroup structure makes individual model statistically less efficient.
Qualitative Results. In Figure 9, we present the predictions from ITR and pop model for two
example patients. Only the last 20 observations (black dots) are plotted for the training set. The
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red points are creatinine levels that are reserved for the test set. The dashed lines are the predicted
baseline progressions and the solid lines are the final predictions of the creatinine levels. Prescriptions
of treatments are shown as vertical dashed lines. Treatment response curves are plotted on the right
of the trajectory predictions. Ribbons denote the 95% credible intervals.
As an aid for our analysis, we plot a heat map of the renal SOFA (Sequential Organ Failure
Assessment) scores (Vincent et al., 1996) above the trajectory predictions. Renal SOFA scores,
ranging from 0 to 4, is typically used in the ICU to capture the patient’s kidney function. A higher
score represents a higher risk for kidney failure. From day 32 to 36, the baseline progression for
patient 44 inferred by ITR increases to a greater extent in comparison with the baseline progression
inferred by pop model. The ITR’s inference aligns with the clinical expectation that the patient’s
creatinine levels will increase without treatment since the patient has a renal SOFA score of 4 during
this time period. In comparison to the treatment response curve estimated by pop model, the response
curve estimated by ITR indicates that the patient is less responsive to CVVHD. The difference
between these two estimates could be explained by the fact that although this patient has an overall
averaged renal SOFA of 3.9, the average for population is 2.5. For patient 228, who was documented
as a Chronic Kidney Disease (CKD) patient, the baseline progression inferred by ITR increases to a
smaller extent in comparison with the baseline progression inferred by pop model. ITR aligns with
the clinical expectation that this patient’s creatinine levels will remain stable with RRT treatment
since RRT is a modality used to maintain creatinine levels within the normal range in CDK patients
with end stage renal disease.
More broadly, we expect the patients to be less responsive to RRT if they have more severe kidney
dysfunction. In Figure 10 (a), we plot the estimated treatment response curves associated with the
patient’s minimum renal SOFA score. A renal SOFA score was calculated each time the creatinine
level was measured following the first test that indicated an elevated creatinine level. The curves are
normalized over the patient’s initial creatinine level at the time when RRT is initiated. We observe
that patients with more severely compromised kidney function (as indicated by higher SOFA scores)
are more resistant to RRT. In Figure 10(b), we plot the curves for AKI patients, identified by the
ICD-92 diagnosis code 584, and observe that the AKI patients who also have CKD (identified by
ICD-9 codes 585, 585.1–585.6, and 585.9) tend to be more resistant to RRT than those who only
have AKI.
Figure 10: Association of responsiveness to CVVH with kidney disease severity
2. http://www.cdc.gov/nchs/icd/icd9.htm
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Figure 9: Comparison of ITR vs. pop model predictions on two example trajectories for creatinine
level. The black points are measurements in the training set and red points are measure-
ments in the test set The dashed lines are the predicted baseline progressions and the
solid lines are the final predictions of the creatinine levels. Prescriptions of treatments
are shown as vertical dashed lines. Treatment response curves are plotted on the right of
the trajectory predictions. Ribbons denote the 95% credible intervals. Heat maps with
the colors light yellow (renal SOFA of 0) to red (renal SOFA of 4) are plotted above the
trajectory predictions.
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4.3 Observational Study: Estimating Heterogenous Response Curves to Diuretics
We also evaluate the proposed model on the task of estimating patients’ responses to diuretics,
particularly Lasix (furosemide), a common treatment to remove excess fluid that has accumulated in
critically ill patients after aggressive fluid resuscitation therapies. Fluid overload has been shown to
be associated with worse outcomes in many studies. For example, Acheampong and Vincent (2015)
show that a positive fluid balance is an independent prognostic factor for mortality in septic patients
in the ICU. Although Lasix can be used to treat fluid overload, it should only be used when it is
effective (Cerda et al., 2010). Persistent use of diuretics in renal failure or heart failure patients who
do not respond to diuretics may delay the initialization of dialysis, another modality that can be
used for managing fluid balance. This delay can lead to worse patient outcomes (Cerda et al., 2010).
Thus, an individualized assessment tool to predict whether a patient will respond to diuretics can
greatly impact the management of fluid status.
Datasets. We fit our models on electronic health record data from the MIMIC-II Clinical
Database. We estimate the effects of Lasix at four different dose levels: <= 5 ml/hr, <= 10 ml/hr,
<= 30 ml/hr, and > 30 ml/hr. We use fluid balance since ICU admission as the patient’s outcome.
We calculate the fluid balance by subtracting the cumulative urine outputs at each time point from
the cumulative fluid inputs. We calculate the fluid balance one day before the Lasix is first prescribed.
Afterwards, we compute the fluid balance at each time the urine output is updated in the database.
We include the patients who are prescribed Lasix. We exclude the patients’ data when other
modalities are prescribed for managing the fluid balance, e.g. dialysis. The dataset contains 231
trajectories with a total of 88, 578 observations of fluid balance. Each individual trajectory has an
average duration of 51 days. The datasets contains a total of 1, 738 instances of Lasix <= 5 ml/hr,
1, 146 of Lasix <= 10 ml/hr, 829 of Lasix <= 30 ml/hr, and 124 of Lasix > 30 ml/hr. Fluid balances
were standardized by the population mean of 14.71 and standard deviation of 15.23.
Experimental setup. For the fixed-effects component in the baseline progression, we still use
p = 4 covariates: age, weight, time and 1 for the intercept. We posit a non-informative Normal-
inverse-Wishart base distribution NIW(0, 1, p+2, Ip) for the regression coefficients. We posit a strong
prior N (log(0.12), 0.32) on the transformed scale parameters in the exponential Gaussian process
kernel and a non-informative prior N (logit(0.5), 4) on the transformed smooth parameters.
For the treatment response model, we posit a Gaussian prior on the peak effects with the means
chosen by the domain expert. Specifically, these were set as N (−1, 1), N (−2, 1), N (−3, 1), and
N (−4, 1) from low to high dose level of Lasix, respectively. Similarly, we posit a Gaussian prior on
the change points with means chosen by the domain expert based on the expected duration over
which the treatment takes effect. Specifically, these were set as N(12 hrs, 100 hrs), N(14 hrs, 100 hrs),
N(16 hrs, 100 hrs), and N(18 hrs, 100 hrs). We posit non-informative Gaussian priors N (logit(0.5), 4)
for the two steepness parameters and the ratio of the long-term effect to the peak effect.
For the noise, we posit an Inverse-Gamma prior IG(1, 1) on the variances of the i.i.d. noises. We
posit strong priors N (log(0.12), 0.32) on the scale parameters for the time-dependent noises, and
non-informative priors N (logit(0.5), 4) for the smooth parameters.
Evaluation. We use prediction error on a held-out test set to compare the proposed model to
the baseline models. We treat the first 100 observations from each individual as training data and
the remainder as test data. Predictions of the measurements are made under the treatment strategy
prescribed in the test set. Since urine output are measured on average 7 times a day and management
decisions are made at the granularity of hours, we report prediction errors for 24 hours following the
end of training. Then, we follow the same procedures described in Section 4.2 to evaluate the models.
Quantitative Results. In Figure 11(a), we report the mean prediction errors with the 95%
credible intervals for ITR and the three baseline models. ITR outperforms the three baseline models
significantly. Pop model performs the worst across the four models statistically significantly. In
Figure 11(b), we demonstrate how the performance of prediction varies across the different models
when the number of observations per treatment type varies. Individual model performs the worst at
18
Figure 11: Comparison of ITR vs. baselines prediction errors on fluid balance.
the beginning due to the lack of data. As more data are obtained, individual model performs better
than pop and sub-pop models, and it eventually performs similarly as ITR. Performance of pop model
is comparable to ITR when there are few data, but decreases when enough data are given to show
the diversity across individuals. It is because pop model does not have the flexibility to individualize
baseline progressions and treatment response curves like ITR.
Qualitative Results. In Figure 12, we present the predictions from ITR and pop model for
two example patients. For patient 69, the treatment response curve estimated by ITR indicates
that the patient is more responsive to ≤ 5ml/hr of Lasix in comparison with the response curve
estimated by pop model. The ITR’s estimate aligns with the clinical expectation that the patient
will be responsive to low dose levels of Lasix since the patient has an overall averaged renal SOFA
score of 0. The reason Pop model estimates a less responsive curve for low dose level of Lasix could
be explained by the fact that the average renal SOFA for population is 1.2. For patient 30, ITR can
not predict the final outcomes accurately because the creatinine level increases unexpectedly when
the patient develops AKI during the time of prediction. The renal SOFA score also has a sudden
increase from 1 to 4 within a day. However, in contrast with the estimates from pop model, the high
stabilized baseline progression and the resistant response curve for high dose level of Lasix (between
10ml/hr and 30ml/hr) estimated by ITR potentially indicate the decreased kidney function.
More broadly, response to diuretics can indicate lesser severity of kidney disease (Cerda et al.,
2010). In Figure 13(a), we plot the estimated treatment response curves associated with the patient’s
minimum renal SOFA score. The curves are normalized over the patient’s initial fluid balance at the
time when Lasix was prescribed. We observe that the effect of diuretics on fluid balance tends to
decrease when the patient’s renal function declines. In Figure 13(b), we also see that the patients
who have both AKI and CKD tend to be more resistant to Lasix than those who only have AKI.
In addition, dialysis may be initiated as an alternative modality to remove the the excess fluid if
the patients are observed to be resistant to diuretics. To validate this, in Figure 13(c) we plot the
estimated treatment response curves associated with an indicator whether the patient is prescribed
dialysis in the future or not. As we expect, the patients who are more responsive to diuretics do not
need dialysis for further treatments.
5. Conclusion
In this paper, we have developed a novel Bayesian nonparametric method for estimating treatment
response curves from sparse observational time series. We leverage hierarchical priors that allow
individual-specific estimates while borrowing information across individuals. Notably, we maintain
the full posterior rather than just point estimates. We demonstrate significant gains in performance
for modeling creatinine and effects of treatments used for managing kidney function, as well as effects
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Figure 12: Comparison of ITR vs. pop predictions on two example trajectories for fluid balance. The
black and red points are training and predicting measurements, respectively. The dashed
lines are the predicted baseline progressions and the solid lines are the final predictions
of the creatinine levels. Prescriptions of treatments are shown as vertical dashed lines.
Treatment response curves are plotted on the right of the trajectory predictions. Ribbons
denote the 95% credible intervals for the prediction. Heat maps with the colors light
yellow (renal SOFA of 0) to red (renal SOFA of 4) are plotted above the trajectory
predictions.
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Figure 13: Association of patients’ responsiveness to Lasix ≤ 30ml/hr with patients’ kidney disease
severity (No patients in the dataset start with renal SOFA score 4).
of diuretics used for managing fluid balance. As future work, we plan to evaluate these models
on other subpopulations with MIMIC and test sensitivity to different modeling choices. Access to
accurate models for estimating treatments responses at the individual are critical for designing new
personalized treatments.
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Appendix A. Transformation of Constrained Variables
The treatment-response curves were characterized using a parametric form containing constrained
variables (e.g., α2, α3 ∈ (0, 1)). To simplify inference, we transform the support of these variables
such that they live in the real space R and posit (Gaussian) priors on these transformed variables.
Given a random variable X ∈ Rd with continuous probability density function fX(x) and support
X = supp(fX(x)), we can define a random variable Y ∈ Rd such that Y = T (X) with support
Y = supp(fY (y)) and a one-to-one differentiable function T : X → Y. Then based on Olive (2014),
Y has the probability density function
fY (y) = fX(T
−1(y))|det JT−1(y)|,
where the adjustment term is the absolute determinant of the Jacobian:
JT−1(Y ) =

∂T−11
∂y1
· · · ∂T−11∂yd
...
...
∂T−1d
∂y1
· · · ∂T
−1
d
∂yd

Let us first consider the univariate variable α2 ∈ (0, 1) from the g function we defined in Section 2.2.
We transform it to be α′2 = logit(α2), and posit a Gaussian prior on it. That is, α′2 ∼ N (α′2;µα′2 , σ2α′2).
The Jacobian adjustment is calculated as |det J(logit(α2))| = 1/α2(1 − α2). Thus we get the
probability density function
p(α2) = N (logit(α2);µα′2 , σ2α′2)/α2(1− α2).
Now let us consider the multivariate variable φ = {α1, α2, α3, γ, b : α1 ∈ R, α2, α3 ∈ (0, 1), γ ∈
R, b/g(γ) ∈ (0, 1)} in the g function. We define a transformation
φ′ = T−1(φ) = {α1, logit(α2), logit(α3), γ, logit(b/g(γ))},
where g(γ) = α1(exp(α2γ/2)− 1)/(exp(α2γ/2) + 1). Since the support of φ′ is Rd, we can posit a
diagonal Gaussian prior φ′ ∼ N (φ′;µφ′ , Dφ′), and calculate the Jacobian
JT−1(φ) =

1 0 0 0 0
0 1/α2(1− α2) 0 0 0
0 0 1/α3(1− α3) 0 0
0 0 0 1 0
bζ
α1
bγζ exp(α2γ/2)
exp(α2γ)−1 0
bα2ζ exp(α2γ/2)
exp(α2γ)−1 ζ
 .
Here, ζ = g(γ)/b(g(γ)− b). Thus we obtain the adjustment |det JT−1(φ)| = |ζ|/α2α3(1−α2)(1−α3)
and reach at the probability density function
p(φ) = N (T−1(φ);µφ′ ,Dφ′)|ζ|/α2α3(1− α2)(1− α3).
We also have constrained parameters in the exponential kernels: σ2 ∈ R+ and ρ ∈ (0, 1) (to be
more precise, σ2ui, ρui and σ2′d , ρ′d). We again define transformations σ
′2 = log(σ2) and ρ′ = logit(ρ)
and posit Gaussian priors on them. Thereafter, we get the densities p(σ2) = N (log(σ2);µσ′ , σ2σ′)/σ2
and p(ρ) = N (logit(ρ);µρ′ , σ2ρ′)/ρ(1− ρ) respectively.
Appendix B. Posterior inference for the individualized treatment
response model
B.1 Blokced Gibbs Sampler for the DPM
We first summarize the blocked Gibbs sampler for general DPMs, and then apply it specifically to ϕi
and φi in our model.
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Given a sufficiently large K, the mixture component parameters θ∗ = {θ∗1 , ..., θ∗K}, the stick
breaking variables V = {V1, ..., VK−1, VK = 1} and the component indicators Z = {Z1, ..., ZN} for
the N observations o = {o1, ..., oN}, the truncated stick-breaking representation of DPM is written
as follows.
p(on|pik, θ∗k) =
K∑
k=1
pikp(on|θ∗k) (13)
pik = Vk
∏
j<k
(1− Vj), for k = 1, ...,K
Vk ∼ Beta(1,M), for k = 1, ...,K − 1
Then the blocked Gibbs sampler is formulated by the following steps.
1. Independently sample θ∗k from p(θ
∗
k|Z,V ,o) ∝ G0(θ∗k)
∏N
n=1 p(on|θ∗k)1{Zn=k};
2. Independently sample vk from p(Vk|Z,θ,o) = Beta(1 + nk,M +
∑K
j=k+1 nj), where nj is the
number of observations in cluster j;
3. Independently sample zn from p(Zn = k|V ,θ,o) = pikp(on|θk), where pik = Vk
∏
j<k(1− Vj).
Note that step 1 can be derived in closed form if the base distribution G0 is chosen to be conjugate—a
choice we make in (8). Now let us specify the samplers for the DPM parameters in our model.
We first describe the steps of sampling DP mixtures for ϕi’s. Suppose K1 is the truncation
level we assume for the baseline progression. Denote the mixture component hyperparameters as
θ∗ϕ = {β∗b ,Σ∗b ,µ∗σ′u ,µ∗ρ′u}, where β∗b = {β∗b1 , ..., β∗bK1 }, Σ
∗
b = {Σ∗b1 , ...,Σ∗bK1}, µ
∗
σ′u
= {µ∗σ′u1 , ..., µ
∗
σ′uK1
},
µ∗ρ′u = {µ∗ρ′u1 , ..., µ
∗
ρ′uK1
}. Further, the stick breaking variables Vϕ = {Vϕ1 , ..., VϕK1−1 , VϕK1 = 1} and
the component indicators Zϕ = {Zϕ1 , ..., ZϕI} for the parameters ϕ = {ϕ1, ..,ϕI}.
1. Independently sample β∗bk , Σ
∗
bk
from
p(β∗bk ,Σ
∗
bk
|Zϕ,Vϕ,ϕ) = NIW(β∗bk ,Σ∗bk |mk, κk, νk,Sk)
mk =
κ0β0 +
∑I
i=1 βi1{Zϕi=k}
κk
κk = κ0 +
I∑
i=1
1{Zϕi=k}
νk = ν0 +
I∑
i=1
1{Zϕi=k}
Sk = S0 +
I∑
i=1
βiβ
T
i 1{Zϕi=k} + κ0β0β
T
0 − κkmkmTk ;
2. Independently sample µ∗σ′uk
from
p(µ∗σ′uk
|Zϕ,Vϕ,ϕ) = N (µ∗σ′uk ;mσ′u , sσ′u)
mσ′ =
σ2σ′u0
µσ′0 + σ
2
σ′0
∑I
i=1 log(σ
2
ui)1{Zϕi=k}
σ2σ′u0
+
∑I
i=1 σ
2
σ′0
1{Zϕi=k}
sσ′u =
σ2σ′u0
σ2σ′0
σ2σ′u0
+
∑I
i=1 σ
2
σ′0
1{Zϕi=k}
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3. Independently sample µ∗ρ′uk
from
p(µ∗ρ′uk
|Zϕ,Vϕ,ϕ) = N (µ∗ρ′uk ;mρ′u , sρ′u)
mρ′ =
σ2ρ′u0
µρ′0 + σ
2
ρ′0
∑I
i=1 logit(ρui)1{Zϕi=k}
σ2ρ′u0
+
∑I
i=1 σ
2
ρ′0
1{Zϕi=k}
sρ′u =
σ2ρ′u0
σ2ρ′0
σ2ρ′u0
+
∑I
i=1 σ
2
ρ′0
1{Zϕi=k}
4. Independently sample Vϕk from
p(Vϕk |Zϕ,θ∗ϕ,ϕ) = Beta(1 + n1k,M1 +
K1∑
j=k+1
n1j),
where n1j is the number of ϕi’s that were assigned to cluster j;
5. Independently sample Zϕi from
p(Zϕi = k|Vϕ,θ∗ϕ,ϕ)
= ω1kN (βi;β∗bk ,Σ∗bk)N (log(σ2ui);µ∗σ′uk , σ
2
σ′u0
)N (logit(ρui);µ∗ρ′uk , σ
2
ρ′u0
)/σ2ui(1− ρui)2,
where ω1k = Vϕk
∏
j<k(1− Vϕj ).
Now we describe the steps of sampling DP mixtures for φid’s. Let K2d be the truncation
level assumed for the DPM prior on the dth treatment-response for (d = 1, ..., D). Denote the
mixture component hyperparameters as θ∗φd = {µ∗φ′d}, where µ
∗
φ′d
= {µ∗φ′d1 , ...,µ
∗
φdK2d
}. Further,
the stick breaking variables Vφd = {Vφd1 , ..., VφdK2d−1 , VφdK2d = 1} and the component indicators
Zφd = {Zφ1d , ..., ZφId} for the parameters φd = {φ1d, ..,φId}.
6. Independently sample µ∗φ′d from
p(µ∗φ′d |Zφd ,Vφd ,φd) = N (µ
∗
φ′d
;mφ′d ,Sφ′d)
Sφ′d = (D
−1
0d
+D−1φ′0
I∑
i=1
1{Zφid=k})
−1
mφ′d = Sφ′d(D
−1
0d
µ0d +D
−1
φ′0
I∑
i=1
T−1(φid)1{Zφid=k}),
where T−1(φid) = {α1id , logit(α2id), logit(α3id), γid, logit(bid/g(γid))};
7. Independently sample Vφdk from
p(Vφdk |Zφd ,θ∗φd ,φd) = Beta(1 + n2dk,M2d +
K2d∑
j=k+1
n2dj),
where n2dj is the number of φid’s that were assigned to cluster j;
8. Independently sample Zφid from
p(Zφid = k|Vφd ,θ∗φd ,φd) = ω2dkN (T−1(φid);µ∗φ′dk ,Dφ′0)|ζid|/(1− α2id)
4,
where ω2dk = Vφdk
∏
j<k(1− Vφdj ).
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B.2 Gibbs Sampler for the Variables with Conjugate Priors
9. Independently sample βi from
p(βi|θ∗ϕ, Zϕi , σ2i , bi,fi) = N (βi;mbi ,Sbi)
Sbi = (Σ
∗−1
bZϕi
+ σ−2i XiX
T
i )
−1
mbi = Sbi(σ
−2
i XiYbi + Σ
∗−1
bZϕi
µ∗bZϕi ),
where Xi = {Xi1, ...,XiJi}T is a Ji × p matrix, Ybi = Yi − bi − fi is a 1× Ji vector and fi is
defined in Eq. (4). Σ∗−1bZϕi and µ
∗
bZϕi
are sampled in Step 1.
10. Independently sample bi from
p(bi|βi,ϕi, σ2i ,fi) = N (bi;mui ,Sui)
Sui =
(K−1u (tij , tij′ ;ϕi) + σ−2i IJi)−1
mui = σ
−2
i SuiYui ,
where Yui = Yi −Xiβi − fi is a 1× Ji vector.
11. Independently sample σ2i from
p(σ2i |βi, bi,f ′i) = IG(s + Ji/2, ν + YeiY Tei /2),
where Yei = Yi−Xiβi− bi−f ′i is a 1×Ji vector and the auxiliary variable f ′i is sampled from
p(f ′i |βi,φi,σ2f ,ρ2f , σ2i , bi) = N (f ′i ;mfi ,Sfi)
Sfi =
(K−1f (tij , tij′ ;σ2f ,ρ2f ) + σ−2i IJi)−1
mfi = Sfi
(
σ−2i Yfi +K−1f (tij , tij′ ;σ2f ,ρ2f )m(ti;φi)
)
,
where Yfi = Yi −Xiβi − bi is a 1× Ji vector.
12. Sample M1 from
p(M1|η1, k1) ∼ c1 + k1 − 1
c1 + k1 − 1 + I(d1 − log(η1))Gamma(c1 + k1, d1 − log(η1))
+
I(d1 − log(η1))
c1 + k1 − 1 + I(d1 − log(η1))Gamma(c1 + k1 − 1, d1 − log(η1)),
where the auxiliary variable η1 ∼ Beta(M1 + 1, I), the prior for M1 is Gamma(c1, d1), and k1
is the current cluster number for ϕi’s.
13. Independently sample M2d from
p(M2d|η2d, k2d) ∼ c2d + k2d − 1
c2d + k2d − 1 + I(d2d − log(η2d))Gamma(c2d + k2d, d2d − log(η2d))
+
I(d2d − log(η2d))
c2d + k2d − 1 + I(d2d − log(η2d))Gamma(c2d + k2d − 1, d2d − log(η2d)),
where the auxiliary variable η2d ∼ Beta(M2d + 1, I), the prior for M2d is Gamma(c2d, d2d), and
k2d is the current cluster number for φid’s.
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B.3 Metropolis-Hastings Sampler in the Non-Conjugate Case
We use blocked Metropolis-Hastings to sample the remaining parameters i.e., parameters for which we
cannot obtain the conditional distributions in closed-form: σ2ui , ρui , σ
2
′d
, ρ′d , and φid’. Specifically,
for a variable x, we propose a candidate value xcand from a proposal distribution p(xcand|x) and
accept the candidate with probability
min{1, pi(x
cand)p(x|xcand)
pi(x)p(xcand|x) },
where pi(·) is the full joint posterior defined in Eq. (12). Below, we choose different proposal
distributions for x for the following three different types of support.
• For x ∈ R, we propose new sampler from N (x, 0.32), which is a symmetric proposal distribution.
• For x ∈ R+, we propose new sampler from N (x, 0.32)/Φ(x, 0.32), where Φ is the CDF of the
normal distribution. This is not a symmetric proposal distribution.
• For x ∈ (0, 1), we propose a new sampler from N (x, 0.152) and “reflect” it by 0 or 1 to make it
fall back in (0, 1). This is so-called “reflected normal”, and the reflection can be done multiple
times if needed. It is still a symmetric proposal distribution.
We experimented with a few different choice of values for the variance parameter in the proposal
distribution. The values selected above yielded reasonable acceptance rates in the range of 0.14−0.22.
In detail, the sampling for the remainder of the parameters proceeds as follows.
14. Propose σ2
cand
ui ∼ N (σ2ui , 0.32)/Φ(σ2ui , 0.32), ρcandui ∼ N (ρui , 0.152) an reflect ρcandui into (0, 1).
We accept the proposal with probability of min{1, pi(σ
2cand
ui
,ρcandui
)Φ(σ2ui
)
pi(σ2ui
,ρui )Φ(σ
2cand
ui
)
}, where pi(σ2·ui , ρ·ui) is
N (Yui ;0,Ku(βi, σ2·ui , ρ·ui)+σ2iIJi)N ( log(σ2·ui);µσ′ui , σ2σ′u0)N (logit(ρ·ui);µρ′ui , σ2ρ′u0)/σ2·ui(1−ρ·ui)2.
15. Propose σ2
cand
′ ∼ N (σ2′ , 0.32ID)/Φ(σ2′ , 0.32ID) and ρcand′ ∼ N (ρ′ , 0.152ID) and reflect ρcand′
into (0, 1)D. We accept the proposal with probability of min{1, pi(σ
2cand
′ ,ρ
cand
′ )Φ(σ
2
′ ,0.3
2ID)
pi(σ2
′ ,ρ′ )Φ(σ
2cand
′ ,0.3
2ID)
},
where pi(σ2
·
′ ,ρ
·
′) is
I∏
i=1
N (Yei ;m(ti,φi),K′(σ2·′ ,ρ·′) + σ2iIJi) D∏
d=1
N ( log(σ2·′d);µ′1 , σ2′1)
N (logit(ρ·′d);µ′2 , σ2′2)/σ2·′d(1− ρ·′d)2.
16. Propose {αcand1id , αcand2id , αcand3id , γcandid , bcandid /g(γcandid )} ∼ N ({α1id , α2id , α3id , γid, bid/g(γid)},
Diag(0.32, 0.152, 0.152, 0.32, 0.152)), αcand2id ∼ N (α1id , 0.32) and reflect αcand2id , αcand3id and bcandid /g(γcandid )
into (0, 1) individually. We accept the proposal with probability of min{1, pi(φcandi )pi(φi) }, where
pi(φ·i) is
N (Yei ;m(ti,φ·i),Kf (σ2′ ,ρ′) + σ2iIJi) D∏
d=1
N (T−1(φ·id);µφ′id ,Dφ′0)|ζ ·id|/(1− α·2id)4.
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